Anatara Lifesciences (ASX:ANR) has provided an update on the recruitment progress for Stage 2 of its pivotal GaRP-IBS - irritable bowel syndrome - trial.

Australian digital inhaler technology company Adherium (ASX:ADR) has entered into a $674,000 R&D loan facility with Endpoints Capital.

Acrux CEO and managing director Michael Kotsanis said, “We are very pleased to receive FDA approval for another ANDA product which has been developed in house by the Acrux R&D team."

AusBiotech CEO Rebekah Cassidy expressed support for the review, emphasising the need for a unified approach to enhance Australia's R&D ecosystem.

Brisbane health-tech company WearOptimo has unveiled the initial $7 million phase of its advanced manufacturing facility to produce its microwearable sensor.

Dr Dell Kingsford Smith joins the AusBiotech board with more than 20 years of experience in clinical and commercial strategy across medical technology, pharmaceuticals, and vaccines.

Respiratory imaging technology company 4DMedical Limited (ASX:4DX) has signed a commercial contract with Perth Radiological Clinics to deliver its XV Technology-enabled ventilation reports across an initial 16 clinics in Perth.

Regenerative medicine company Orthocell (ASX:OCC) has announced the successful completion of its Remplir 510(k) nerve repair study.

Celosia Therapeutics, an Australian biotechnology company developing advanced gene therapies for neurodegenerative diseases, has raised $16.75 million to advance its program for amyotrophic lateral sclerosis disease.

AusBiotech and MTPConnect jointly delivered Australia’s first National Biotech and Medtech Development and Commercialisation Summit in Canberra last week.

Australian-supported research recently published in three leading medical journals has confirmed positive Phase 3 clinical trial results for a triple combination that could revolutionise the management and treatment of high blood pressure.

Australian antiviral drug development company Island Pharmaceuticals Ltd (ASX:ILA) has announced that ISLA-101 has shown safety and anti-dengue activity in the Phase 2a cohort of the PROTECT Phase 2a/b trial.

Australian clinical-stage biotechnology company Vaxxas has expanded its global intellectual property portfolio to 42 patents, supporting its exclusive claim to manufacture and sell its proprietary vaccination technology, the HD-MAP, in the US, Europe, Asia and Australia.

GE HealthCare and Peter MacCallum Cancer Centre have announced a partnership under which the Melbourne-based facility will evaluate a new positron emission tomography and computed tomography technology

“Professor David Thomas is a visionary leader in genomic cancer medicine, whose work has not only transformed outcomes for patients but has also positioned Australia as a global leader in precision oncology," said AusBiotech CEO Rebekah Cassidy.

Professor David Thomas said, “We are on the cusp of a new era in cancer care. It’s imperative to integrate this approach as mainstream care for all Australians.” 

CEO and managing director Brent Barnes said, “With the growing sales momentum of APAS, we believe now is the ideal time to streamline and simplify communications with our customers and shareholders under the unified identity of Clever Culture Systems.”